BCAAs in Concussion 3.0
Key facts
- Who runs it
- Akiva Cohen
- Where
- Havertown, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 150 people, planned
- Started
- 5 Aug 2026
- Expected to end
- Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- BCAA
- Placebo
- Record updated
- 3 September 2026
Who can take part
- Age
- 11 years to 23 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Males and females,11 - 23 years of age
- Weigh at least 40kg
- Meeting concussion criteria for the American Congress of Rehabilitative Medicine; One or more clinical signs or two or more acute symptoms with at least one VVE abnormality
- Present within 4 days of injury
- Post-menarchal females must have a negative urine pregnancy test
- Informed consent by the participant, or for participants <18 years old both informed consent by a parent/guardian and child assent
Who cannot take part
- Prior concussion or TBI within 90 days
- Any investigational drug use within 30 days prior to enrollment
- Known history of maple syrup urine disease or known family history of maple syrup urine disease
- Evidence of moderate or severe TBI, including GCS <13, TBI requiring hospital admission, or TBI requiring neurosurgical intervention
- Participants who are pregnant, planning on becoming pregnant during the study duration, or breastfeeding
- Non-English speaking participants or parent/guardian
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 11 and 23 years old?
This trial is currently available in United States.
- Children's Hospital of PhiladelphiaHavertown, United StatesContact: Daniel Corwin, MDTaking people
About the trial
What the trial wants to find out
This study is a randomized, placebo-controlled, double-blinded, therapeutic exploratory clinical trial of branched chain amino acids (BCAAs) in the treatment of concussion. The aim of the study is to determine whether administration of high-dose BCAAs compared to placebo promotes concussion recovery.
The 2 groups in the trial
- Drug: Branched Chain Amino AcidsTreatment being tested
The three BCAAs will be combined together into a powder formulation.
Treatment: BCAA
- PlaceboPlacebo, for comparison
The placebo formulation will have similar taste, texture, consistency and appearance as the BCAA formulation.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- HIT HEADS 3.0: Head Injury Treatment: A Randomized, Placebo-controlled, Double-blinded, Therapeutic Clinical Trial of Branched Chain Amino Acids (BCAAs) in the Treatment of Concussion
- Criteria questions
- Built from NCT07670195, who can take part
- Record updated
- 3 September 2026